<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="980">
  <stage>Registered</stage>
  <submitdate>28/07/2004</submitdate>
  <approvaldate>28/07/2004</approvaldate>
  <actrnumber>ACTRN12606000112561</actrnumber>
  <trial_identification>
    <studytitle>Cetuximab and Best Supportive Care Compared with Best Supportive Care Alone in Treating Patients with Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer.</studytitle>
    <scientifictitle>Phase III Randomised Study of Cetuximab and Best Supportive Care Versus Best Supportive Care Alone in survival of Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer.</scientifictitle>
    <utrn />
    <trialacronym>CO.17</trialacronym>
    <secondaryid>Bristol Myers-Squibb, Canada: BMS-CA225-025</secondaryid>
    <secondaryid>ImClone: IMCL-CAN-NCIC-CO17</secondaryid>
    <secondaryid>National Clinical Trials Registry: NCTR576</secondaryid>
    <secondaryid>National Cancer Institute of Canada: CAN-NCIC-CO17</secondaryid>
    <secondaryid>Bristol Myers Squibb, Canada: BMS-CA225-025</secondaryid>
    <secondaryid>Australasian Gastro-Intestinal Trials Group: AGITG-CAN-NCIC-CO17</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Colorectal Cancer
- stage IV colon cancer
- recurrent colon cancer
- recurrent rectal cancer
- stage IV rectal cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a randomised, open-label, multicenter study.  Patients are stratified according to participating center and ECOG performance status (0 or 1 vs 2).  Patients are randomised to 1 of 2 treatment arms.

Arm I:  Patients receive an initial loading dose of cetuximab (Erbitux) IV over 120 minutes on day 1.  Patients continue to receive maintenance infusions of cetuximab IV over 60 minutes weekly.  Patients also receive best supportive care, defined as measures designed to provide palliation of symptoms and improve quality of life as much as possible.

Arm II:  Patients receive best supportive care as in arm I.  In both arms, treatment continues in the absence of disease progression or unacceptable toxicity.  

Quality of life is assessed at baseline, and then at 4, 8, 16, and 24 weeks (or until deterioration to ECOG PS 4 or hospitalisation for end of life care).  Patients are followed up every 4 weeks.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Compare survival of patients with metastatic epidermal growth factor receptor-positive colorectal cancer treated with cetuximab and best supportive care vs best supportive care alone.</outcome>
      <timepoint>Measured from enrolment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the time to disease progression in patients treated with these regimens.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the objective response rate in patients treated with these regimens.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the quality of life of patients treated with these regimens. </outcome>
      <timepoint>At week 4, 8, 16 and 24 of treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compare the health utilities of patients treated with these regimens throughought treatment and follow up.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Conduct a comparative economic evaluation in patients treated with these regimens, throughtout treatment and follow up.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine the safety profile of cetuximab in these patients throughout treatment and follow up.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically confirmed colorectal cancer- Metastatic disease- Epidermal growth factor receptor (EGFR)-positive by immunochemistry- Measurable or evaluable disease- Not amenable to standard curative therapy- Best supportive care is the only available option- Must have received a prior thymidylate synthase inhibitor (eg: fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) in the adjuvant or metastatic setting- Combination therapy with oxaliplatin or irinotecan allowed- Must have failed* a prior regimen containing irinotecan and a prior regimen containing oxaliplatin for metastatic disease OR relapsed within 6 months after an adjuvant regimen containing irinotecan or oxaliplatin OR have documented unsuitability for such regimens.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No symptomatic CNS metastases.- Any condition that does not permit compliance with the protocol*NOTE: Failure is defined as either disease progression (clinical or radiological) or intolerance to the regimen.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central Randomisation by fax</concealment>
    <sequence>Dynamic Minimisation Procedure</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/11/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>500</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>National Cancer Institute of Canada</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Canada</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Cancer Institute of Canada</fundingname>
      <fundingaddress />
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>National Cancer Institute of Canada</fundingname>
      <fundingaddress />
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Australasian Gastro-Intestinal Trials Group</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Therapeutic options for patients with metastatic colorectal cancer whose cancers have progressed after treatment with standard therapies are limited. Cetuximab therapy is a new treatment targeting the epidermal growth factor receptor (EGFR, a protein on the surface of many cancer cells). Cetuximab can attach to this protein and may stop cancer growth. This study will examine the effect of cetuximab on length and quality of life in people with advanced EGFR positive colorectal cancer whose cancer has progressed after chemotherapy.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Canberra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>29/10/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>26/08/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St George Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>10/10/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>2/07/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nepean Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>28/08/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Port Macquarie Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/08/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/04/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Institute</ethicname>
      <ethicaddress />
      <ethicapprovaldate>16/09/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/09/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>17/09/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin and Repatriation Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>23/10/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>2/02/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate>10/12/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cabrini Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>8/09/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>12/12/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Brisbane Adult Mater Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>18/02/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>25/08/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>9/12/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/08/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>16/03/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Fremantle Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>16/09/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St John of God Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/08/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hobart Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/10/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Launceston General Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>6/11/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>15/03/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Palmerston North Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>8/03/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>National Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>10/05/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Singapore</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Chris Karapetis</name>
      <address>Department of Medical Oncology
Flinders Medical Centre
Flinders Drive
Bedford Park Adelaide SA 5042</address>
      <phone>+61 8 82048997</phone>
      <fax>+61 8 82044997</fax>
      <email>c.karapetis@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Chris Karapetis</name>
      <address>Department of Medical Oncology
Flinders Medical Centre
Flinders Drive
Bedford Park Adelaide SA 5042</address>
      <phone>+61 8 82048997</phone>
      <fax>+61 8 82044997</fax>
      <email>c.karapetis@flinders.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>